New CLL/SLL Drug Compares Well to Ibrutinib in Clinical Study
A large phase 3 clinical trial suggests that pirtobrutinib (sold under the brand name Jaypirca) is being studied as a poss...
Continue with Facebook
Continue with your email
Become a member to get even more